Ablynx appoints Dr Andreas Menrad as its new chief scientific officer
pharmafile | February 15, 2012 | Appointment | Business Services, Research and Development, Sales and Marketing | Abllynx, Menrad, nanobody
Dr Andreas Menrad has joined the Belgium-based firm Ablynx as its new chief scientific officer.
Dr Menrad has over 20 years’ experience in the pharma industry, and has worked in drug discovery and helped treatments progress from pre-clinical development.
Ablynx is currently developing a portfolio of nanobody-based programmes in a number of major disease areas, including inflammation, haematology, oncology and pulmonary disease.
He will head up the firm’s research activities, be responsible for the ongoing development of its Nanobody platform, and identify and prioritise new therapeutic programmes.
Prior to joining Ablynx, Dr Menrad was at Genzyme for five years, where he held the position of general manager and VP of antibody therapeutics. Previously he held senior research positions with Schering AG.
Related Content

Sanofi makes moves with strategic $2.4 billion Ablynx nanobody deal
Sanofi is steadily recovering from missing out on Actelion to J&J by making another deal, …
Ablynx secures first €1m milestone payment from Novo Nordisk
Ablynx has secured €1 million from Novo Nordisk as it hits its first discovery milestone …

Ablynx and Merck begin immuno-oncology collaboration
Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology …






